New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...